These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
388 related articles for article (PubMed ID: 17582574)
1. Project BioShield: what it is, why it is needed, and its accomplishments so far. Russell PK Clin Infect Dis; 2007 Jul; 45 Suppl 1():S68-72. PubMed ID: 17582574 [TBL] [Abstract][Full Text] [Related]
2. BioShield defence programme set to fund anthrax vaccine. Check E Nature; 2004 May; 429(6987):4. PubMed ID: 15129240 [No Abstract] [Full Text] [Related]
3. U.S. medical countermeasure development since 2001: a long way yet to go. Russell PK; Gronvall GK Biosecur Bioterror; 2012 Mar; 10(1):66-76. PubMed ID: 22455680 [TBL] [Abstract][Full Text] [Related]
4. Office of the Assistant Secretary for Preparedness and Response; HHS Public Health Emergency Medical Countermeasures Enterprise implementation plan for chemical, biological, radiological and nuclear threats. Notice. Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services Fed Regist; 2007 Apr; 72(77):20117-28. PubMed ID: 17520758 [TBL] [Abstract][Full Text] [Related]
5. Medical countermeasures to protect humans from anthrax bioterrorism. Bouzianas DG Trends Microbiol; 2009 Nov; 17(11):522-8. PubMed ID: 19781945 [TBL] [Abstract][Full Text] [Related]
6. Past, imminent and future human medical countermeasures for anthrax. Baillie LW J Appl Microbiol; 2006 Sep; 101(3):594-606. PubMed ID: 16907809 [TBL] [Abstract][Full Text] [Related]
7. Vaccines against biologic agents: uses and developments. Ales NC; Katial RK Respir Care Clin N Am; 2004 Mar; 10(1):123-46. PubMed ID: 15062232 [TBL] [Abstract][Full Text] [Related]
10. Bioterrorism and biological threats dominate federal health security research; other priorities get scant attention. Shelton SR; Connor K; Uscher-Pines L; Pillemer FM; Mullikin JM; Kellermann AL Health Aff (Millwood); 2012 Dec; 31(12):2755-63. PubMed ID: 23213160 [TBL] [Abstract][Full Text] [Related]
11. [The strategic plan for preparedness and response to bioterrorism in Korea]. Hwang HS J Prev Med Public Health; 2008 Jul; 41(4):209-13. PubMed ID: 18664725 [TBL] [Abstract][Full Text] [Related]
12. Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism. Bouzianas DG Expert Rev Anti Infect Ther; 2007 Aug; 5(4):665-84. PubMed ID: 17678429 [TBL] [Abstract][Full Text] [Related]
13. Anthrax countermeasures: current status and future needs. Borio LL; Gronvall GK Biosecur Bioterror; 2005; 3(2):102-12. PubMed ID: 16000041 [TBL] [Abstract][Full Text] [Related]
14. Medical management of biological warfare and bioterrorism: place of the immunoprevention and the immunotherapy. Binder P; Attre O; Boutin JP; Cavallo JD; Debord T; Jouan A; Vidal D Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):401-21. PubMed ID: 12818625 [TBL] [Abstract][Full Text] [Related]
16. Expanding Bioshield: a call for caution. May T Am J Public Health; 2007 Apr; 97 Suppl 1(Suppl 1):S23-5. PubMed ID: 17413075 [TBL] [Abstract][Full Text] [Related]
17. Advances in the development of next-generation anthrax vaccines. Friedlander AM; Little SF Vaccine; 2009 Nov; 27 Suppl 4():D28-32. PubMed ID: 19837282 [TBL] [Abstract][Full Text] [Related]
18. Medical counterbioterrorism: the response to provide anthrax prophylaxis to New York City US Postal Service employees. Partridge R; Alexander J; Lawrence T; Suner S Ann Emerg Med; 2003 Apr; 41(4):441-6. PubMed ID: 12658240 [TBL] [Abstract][Full Text] [Related]